Treatment of huntington disease. Curr Treat Options Neurol. 2013;15(4):424-438.Videnovic, A. (2013). Treatment of huntington disease. Curr. Treat. Options Neurol. 15, 424-438.Videnovic A. Treatment of huntington disease. Curr Treat Options Neurol. 2013 Aug;15(4):424-38....
Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder caused by a CAG trinucleotide expansion in thegene (), which codes for the pathologic mutant HTT (mHTT) protein. Since normal HTT is thought to be important for brain function, we engineered zinc finger protein ...
Although available treatments for Huntington’s disease (HD) are imperfect, thoughtful application can positively impact quality of life. Dopamine antagonists can provide control of the troublesome hyperkinetic movements. These agents can also diminish the frequency of hallucinations and delusions when sympto...
Medical researchers at the University of Alberta have discovered a promising new therapy for Huntington disease that restores lost motor skills and may delay or stop the progression of the disease based on lab model tests, says the lead researcher. Becau
Huntington'S disease: Treatment with muscimol, A GABA-mimetic drug Muscimol, a 纬-aminobutyric acid (GABA) analogue that exerts potent and specific agonist effects on GABA receptors, was administered orally to 10 patients ... I Shoulson,D Goldblatt,M Charlton,... - 《Annals of Neurology》 被...
Credit: Pixabay/CC0 Public Domain Gene therapy targeting the messenger RNA (mRNA) of the mutated huntingtin gene (HTT) can provide long-lasting therapeutic benefit in Huntington's disease after a single administration. An adeno-associated virus (AAV) gene therapy containing a primary artificial micr...
Taking the treatment of Huntington's disease as a paradigm for the study of these ameliorative strategies, this review updates the main conclusions derived from the use of epigenetic drugs at the preclinical and clinical stages, including actions beyond epigenetics. This article is part of a ...
The present invention relates to methods and compositions for the treatment of Huntington's disease. In accordance with one aspect of the invention, there is provided a method of reducing expression of a mutant huntingtin (mHTT) protein in a cell, comprising contacting the cell with an effective...
Irritability is a common neuropsychiatric feature of Huntington's disease (HD), with prevalences varying from 38% to 73%. Similar prevalences of irritability are reported in other neurodegenerative disorders and traumatic brain injury, especially when the frontal lobe is involved. Before therapeutic in...
“There is an urgent need for new, innovative treatments for patients with Huntington’s disease, a genetic disease which causes progressive degeneration of nerve cells in the brain and is associated with significant morbidity and mortality,” said Jim DeMesa, MD, P...